UiPath has reported — and the stock now trades at $17.99, down fractionally on the day but still up 41% over the past month, leaving the fundamental debate wide open.
The most striking feature of the current setup is not the short book, which has actually continued trimming. Short interest edged down roughly 3% on the week to 25.5% of the free float. Availability has loosened further to 228% — more than two shares available for every one already borrowed — and borrow costs remain negligible at 0.45%. That combination signals a short community that is withdrawing pressure, not adding it. Options tell a slightly different story: the put/call ratio closed at 0.61, nearly two standard deviations above its 20-day average of 0.56, and close to its 52-week high of 0.67. Some residual hedging demand remains in the market, even after the print has landed.
The real tension sits between the stock price and what analysts are willing to say about it. UBS moved most aggressively, lifting its target to $19 from $12 the morning after earnings while keeping a Neutral rating. RBC Capital had already raised to $15 from $12 two weeks prior. Yet the consensus mean price target remains at $13.87 — well below the current $17.99. The entire analyst community has been revising upward from a low base, but the aggregate still implies roughly 23% downside from here. BofA carries an Underperform; Morgan Stanley kept an Equal-Weight after cutting its target to $15 in late May. The bull case — 14% revenue growth, ARR at $1.85 billion, an expanding cohort of large customers — points to a company executing better than feared. The bear case centres on a DBNRR sliding to 107%, limited margin expansion, and valuation multiples that have re-rated sharply with the stock up 41% in a month.
Ownership adds one notable data point. Tetragon added aggressively in the June quarter — its combined entities now hold roughly 11% of shares — while founder and CEO Daniel Dines has been selling steadily under a 10b5-1 plan, offloading around 315,000 shares in January at prices between $15 and $17.50. Those were planned sales, not discretionary conviction signals, but they do frame how the largest individual holder viewed fair value at levels now in the rear-view mirror.
The print is therefore less about whether UiPath can grow and more about whether the stock's 41% move has already priced in everything the bulls can reasonably argue — leaving a consensus that still anchors below $14 as the primary test of whether the re-rating holds.
See the live data behind this article on ORTEX.
Open PATH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
